The advent of GLP-1 receptor agonists represents a milestone in the treatment of diabetes and obesity, but it also presents a challenge in balancing the drive for innovation with the need for patient safety. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.